Patent expiry and costs for anti-cancer medicines for clinical use: expiry and costs anti-cancer medicines

Brian Godman; Claudia Wild; Alan Haycox

Patent expiry and costs for anti-cancer medicines for clinical use: expiry and costs anti-cancer medicines

Brian Godman, Claudia Wild, Alan Haycox

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to journal › Editorial › peer-review

60 Downloads (Pure)

Abstract

Drs Brian Godman, Claudia Wild and Alan Haycox review the paper by Venkatesan et al on the patent expiry of (non-) tyrosine kinase inhibitors.

Original language	English
Pages (from-to)	1-3
Number of pages	3
Journal	Generics and Biosimilars Initiative journal
Publication status	Accepted/In press - 17 Mar 2017

Keywords

anti cancer medicines
medicine patents
tyrosine kinase inhibitors

Access to Document

Godman-etal-GABI-2017-Patent-expiry-and-costs-for-anti-cancer-medicines-for-clinicalAccepted author manuscript, 230 KB

Cite this

@article{84f0f4960d6444d599706fa92c6ee893,

title = "Patent expiry and costs for anti-cancer medicines for clinical use: expiry and costs anti-cancer medicines",

abstract = "Drs Brian Godman, Claudia Wild and Alan Haycox review the paper by Venkatesan et al on the patent expiry of (non-) tyrosine kinase inhibitors.",

keywords = "anti cancer medicines, medicine patents, tyrosine kinase inhibitors",

author = "Brian Godman and Claudia Wild and Alan Haycox",

year = "2017",

month = mar,

day = "17",

language = "English",

pages = "1--3",

journal = "Generics and Biosimilars Initiative journal",

issn = "2033-6403",

}

TY - JOUR

T1 - Patent expiry and costs for anti-cancer medicines for clinical use

T2 - expiry and costs anti-cancer medicines

AU - Godman, Brian

AU - Wild, Claudia

AU - Haycox, Alan

PY - 2017/3/17

Y1 - 2017/3/17

N2 - Drs Brian Godman, Claudia Wild and Alan Haycox review the paper by Venkatesan et al on the patent expiry of (non-) tyrosine kinase inhibitors.

AB - Drs Brian Godman, Claudia Wild and Alan Haycox review the paper by Venkatesan et al on the patent expiry of (non-) tyrosine kinase inhibitors.

KW - anti cancer medicines

KW - medicine patents

KW - tyrosine kinase inhibitors

UR - http://gabi-journal.net/

M3 - Editorial

SP - 1

EP - 3

JO - Generics and Biosimilars Initiative journal

JF - Generics and Biosimilars Initiative journal

SN - 2033-6403

ER -

Patent expiry and costs for anti-cancer medicines for clinical use: expiry and costs anti-cancer medicines

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this